# Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

> **NCT05764265** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** LTP001

## Key facts

- **NCT ID:** NCT05764265
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-27
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-05-14
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764265, "Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05764265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*